Belpointe Asset Management LLC Cuts Stock Holdings in Boston Scientific Corporation $BSX

Key Points

• Belpointe Asset Management LLC significantly reduced its stake in Boston Scientific Corporation by 69.7%, now owning only 2,301 shares after selling 5,305 shares in the first quarter.
• Boston Scientific's recent quarterly earnings showed a 22.8% increase in revenue to $5.06 billion, with earnings per share of $0.75, surpassing expectations.
• Various institutional investors, including Vanguard and Goldman Sachs, have increased their positions in Boston Scientific, reflecting strong overall support as they own 89.07% of the company's stock.

Belpointe Asset Management LLC lowered its position in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 69.7% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,301 shares of the medical equipment provider's stock after selling 5,305 shares during the period. Belpointe Asset Management LLC's holdings in Boston Scientific were worth $232,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in BSX. Investment Management Corp VA ADV acquired a new position in shares of Boston Scientific during the fourth quarter valued at $25,000. Sunbeam Capital Management LLC purchased a new position in Boston Scientific during the 4th quarter valued at about $26,000. 1248 Management LLC bought a new stake in shares of Boston Scientific in the 1st quarter valued at approximately $26,000. Y.D. More Investments Ltd bought a new stake in shares of Boston Scientific in the 1st quarter valued at approximately $27,000. Finally, Ameriflex Group Inc. acquired a new stake in Boston Scientific in the 4th quarter worth approximately $31,000. Institutional investors and hedge funds own 89.07% of the company's stock.

Insider Buying and Selling at Boston Scientific

In related news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the company's stock in a transaction on Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $5,231,500.00. Following the transaction, the executive vice president directly owned 178,342 shares of the company's stock, valued at $18,659,923.46. This represents a 21.90% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the sale, the executive vice president directly owned 23,600 shares in the company, valued at approximately $2,469,268. The trade was a 42.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 174,214 shares of company stock worth $18,397,457 in the last 90 days. 0.50% of the stock is currently owned by insiders.

Boston Scientific Stock Performance

NYSE:BSX traded down $0.46 during trading hours on Wednesday, reaching $98.52. The stock had a trading volume of 12,060,694 shares, compared to its average volume of 7,337,055. Boston Scientific Corporation has a 12-month low of $80.64 and a 12-month high of $109.50. The stock has a 50 day simple moving average of $104.62 and a 200 day simple moving average of $102.19. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. The stock has a market cap of $145.98 billion, a P/E ratio of 58.64, a price-to-earnings-growth ratio of 2.38 and a beta of 0.65.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The firm had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $4.89 billion. During the same quarter in the previous year, the business earned $0.62 earnings per share. The company's quarterly revenue was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, research analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently commented on BSX. Truist Financial upped their target price on Boston Scientific from $120.00 to $125.00 and gave the company a "buy" rating in a research note on Thursday, July 24th. Robert W. Baird increased their target price on Boston Scientific from $117.00 to $123.00 and gave the company an "outperform" rating in a research note on Thursday, July 24th. UBS Group raised their price target on Boston Scientific from $130.00 to $135.00 and gave the stock a "buy" rating in a research report on Thursday, July 24th. Oppenheimer upgraded Boston Scientific from a "market perform" rating to an "outperform" rating and increased their price objective for the stock from $118.00 to $125.00 in a report on Monday, September 8th. Finally, Leerink Partnrs upgraded Boston Scientific to a "strong-buy" rating in a research note on Monday, June 16th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and one has given a Hold rating to the company. According to MarketBeat, Boston Scientific currently has an average rating of "Buy" and a consensus price target of $118.04.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.